Journal Article

Role of amiodarone in the management of atrial arrhythmias in adult Fontan patients

Oechslin, Erwin N, Thorne, Sara, Kawada, Satoshi, Khairy, Paul, Silversides, Candice, Nanthakumar, Kumaraswamy, Roche, Lucy, Alonso-Gonzalez, Rafael, Yamamura, Kenichiro, Wald, Rachel M, Swan, Lorna, Downar, Eugene, Harris, Louise, Mondésert, Blandine, Nair, Krishnakumar, Chakraborty, Praloy

2021

Overview

BackgroundPatients with Fontan circulation are known to be at high risk for developing atrial tachyarrhythmias (AAs). Our objective was to examine the efficacy and safety of amiodarone in the management of ATs in adult Fontan patients.MethodsPrimary outcomes of this single-centre, retrospective study included freedom from AAs and incidence of adverse effects of amiodarone on Fontan patients. Heart failure (HF) events and composite outcomes of death from any cause, Fontan revision and heart transplantation were evaluated as secondary outcomes. Predictors of HF and discontinuing amiodarone were also evaluated.ResultsA total of 61 patients (mean age 31.6±11.3 years, 40.9% female), who were treated with amiodarone in between 1995 and 2018, were included. AAs free survival at 1, 3 and 5 years were 76.2%, 56.9% and 30.6%, respectively. During a median follow-up of 50.5 months, 34 (55.7%) patients developed side effects, and 20 (32.8%) patients discontinued amiodarone due to side effects. Thyroid dysfunction was the most common side effect (n=26, 76.5%), amiodarone-induced thyrotoxicosis (AIT) (n=16, 27.1%) being most common thyroid dysfunction. Young age (age <28.5 years) was associated with discontinuing amiodarone (HR 5.50, 95% CI 1.19 to 25.4, p=0.029). AIT significantly increased risk of HF (HR 4.82, 95% CI 1.71 to 13.6, p=0.003).ConclusionsShort-term efficacy of amiodarone in Fontan physiology is acceptable. However, long-term administration is associated with a reduction of efficacy and a significant prevalence of non-cardiac side effects. AIT is associated with exacerbation of HF. The judicious use of amiodarone administration should be considered in this population.

• Publisher: BMJ Publishing Group Ltd and British Cardiovascular Society,BMJ Publishing Group LTD
• Subject: Ablation / atrial flutter / Cardiac arrhythmia / Catheters / Congenital diseases / Congenital heart disease / Drug dosages / drug monitoring / fontan physiology / Heart failure / Laboratories / Liver cirrhosis / Mortality / Patients / Physiology / Thyroid gland / Variance analysis